---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-398015"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2026-09-22T20:41:04+00:00"
generated_at: "2026-09-22T20:42:11.264665+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Halozyme completes $1.5B 1.50% convertible notes due 2033; repurchases existing notes

## Summary
- Issued $1.5B aggregate 1.50% Convertible Senior Notes due 2033; net proceeds ~$1,471.1M.
- Repurchasing $151.7M of 0.25% 2027 Notes and $220M of 1.00% 2028 Notes for ~$217M and $435.5M incl. interest.
- Spent $187.5M on capped call transactions; cap price initially $208.39/share (~90% premium).
- Initial conversion price ~$139.84/share (7.1509 shares per $1,000 principal).
- Remaining proceeds for general corporate purposes, potential acquisitions, and future note repurchases.

## SEC filing metadata
- accession: 0001193125-26-398015
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2026-09-22T20:41:04+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000119312526398015/0001193125-26-398015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000119312526398015/d148460d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-398015
- JSON: https://secwatch.observer/filing/0001193125-26-398015.json
- Plain text: https://secwatch.observer/filing/0001193125-26-398015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.